Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pinterest

One of these stocks is poised to rebound, but the other still looks very risky.

2 Stocks That Are Down 60% (or More) From Their 52-Week Highs

Inovio plans to tackle the omicron variant.

Is Inovio Stock Set to Rebound?

PLYMOUTH MEETING, Pa., Nov. 30, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced the company is rapidly moving to evaluate its COVID-19 DNA vaccine candidates INO-4800 and INO-4802 against the emerging B.1.1.529 (Omicron) variant of concern.

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

Ocugen, Inc.

Both vaccine makers still have big hurdles to jump.

Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen

Gritstone Oncology Inc

Vaxart

3 Vaccine Latecomers That Could Double Your Money

Inovio has been on a rollercoaster ride since the start of the pandemic, and its current aspirations are tied largely to the development of antiviral vaccines. With huge R&D cash burn, the stakes have never been higher for Inovio.

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

AbbVie

Novavax

Pfizer

Sanofi

Could these top biotech stocks be worth investing in for the long term?

5 Biotech Stocks To Check Out In The Stock Market Now

The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing?

Does This News Make Inovio Pharmaceuticals Stock a Buy?

PLYMOUTH MEETING, Pa., Nov. 16, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that several volunteers have been dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase 1b clinical trial (NCT04906629).

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

PLYMOUTH MEETING, Pa., Nov. 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, announced today that eight company-sponsored presentations will be given this week at the 34th International Papillomavirus Conference (IPVC) , which is being held virtually from today, November 15 through Friday, November 19.

INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

The company received a green light to begin a U.S. phase 3 study of its COVID-19 vaccine candidate.

Why Inovio Stock Is Rising Today

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Q3 2021 Results - Earnings Call Transcript

Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares are trading higher Tuesday after the FDA removed a hold on the company's late-stage COVID-19 vaccine trial in the U.S. Inovio Pharmaceuticals is trading up 4.60% at $7.05 at market close Tuesday.

Inovio Pharmaceuticals Sees A Bounce Off Support After COVID-19 Vaccine News

PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat people with cancer, and HPV-associated diseases, today reported financial results for the quarter ended September 30, 2021.

INOVIO Reports Third Quarter 2021 Financial Results

The FDA lifted its hold on the next step of its COVID-19 vaccine trial, although that doesn't mean much at this point.

Why Shares of Inovio Pharmaceuticals Rallied Today

Inovio Pharmaceuticals (INO) stock is pushing higher on Tuesday after providing investors with an update on its Covid-19 vaccine. The post INO Stock: The Covid-19 Vaccine News Helping Inovio Power Higher appeared first on InvestorPlace.

INO Stock: The Covid-19 Vaccine News Helping Inovio Power Higher

The FDA has lifted a partial clinical hold on a late-stage trial of Inovio Pharmaceuticals Inc's (NASDAQ: INO) COVID-19 vaccine in the U.S. Inovio said it now has the authorization to proceed with the trial in the U.S. after 14 months.

FDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial

Shares of Inovio Pharmaceuticals Inc. INO, +0.75% gained 5.9% in premarket trading on Tuesday after the company said it can move forward with the Phase 3 clinical trial for its experimental COVID-19 shot now that the Food and Drug Administration has lifted its partial clinical hold. Inovio had announced the partial clinical hold in September of last year.

Inovio says the FDA lifted its 'hold' on the Phase 3 clinical trial for its COVID-19 shot

PLYMOUTH MEETING, Pa., Nov. 9, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced that the U.S. Food and Drug Administration (FDA) provided authorization to proceed for INOVIO's INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S. The FDA has lifted the partial clinical hold following the FDA's review of additional non-clinical, clinical, and device information provided by INOVIO.

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

PLYMOUTH MEETING, Pa., Nov. 5, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the strategic appointments of new leaders designed to position INOVIO for growth and upcoming commercial operations.

INOVIO Expands Executive Leadership to Prepare for Commercial Operations

PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases, and help treat cancer, and HPV-associated diseases, today announced that it has received authorization from India's Central Drugs Standard Control Organization (CDSCO)'s Drug Controller General of India (DCGI) to proceed with the Phase 3 segment of INOVIO's global Phase 2/3 trial, INNOVATE ( IN OVIO I NO -4800 Va ccine T rial for E fficacy), in India for INO-4800, its DNA vaccine candidate for COVID-19.

INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Inovio Pharmaceuticals (INO) to Report a Decline in Earnings: What to Look Out for

AstraZeneca

MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development program agreement. Under the agreement, MedImmune acquired exclusive rights to INO-3112 immunotherapy, renamed MEDI0457, targeting cancers caused by human papillomavirus types 16 and 18.

AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio

PLYMOUTH MEETING, Pa., Oct. 27, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2021 financial results will be released after the market close on November 9, 2021.

INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced its Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever, completed full enrollment of 220 participants.

News for Inovio Pharmaceuticals Stock (INO)